AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study

AstraZeneca (AZN) announced that a phase III study evaluating its newly approved breast cancer drug, Truqap (capivasertib), for treating advanced or metastatic triple-negative breast cancer (TNBC), has failed to meet its dual primary endpoints.The CAPItello-290 study investigated the safety and efficacy of Truqap in combination with paclitaxel (chemotherapy) versus placebo in combination with paclitaxel for the first-line treatment of patients with locally advanced (inoperable) or metastatic TNBC.In the stu ...